Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Targeting the Mevalonate Pathway for Improved Anticancer Therapy

Author(s): G. Fritz

Volume 9, Issue 5, 2009

Page: [626 - 638] Pages: 13

DOI: 10.2174/156800909789057033

Price: $65

Abstract

The mevalonate pathway is important for the generation of isoprene moieties, thereby providing the basis for the biosynthesis of molecules required for maintaining membrane integrity, steroid production and cell respiration. Additionally, isoprene precursors are indispensable for the prenylation of regulatory proteins such as Ras and Ras-homologous (Rho) GTPases. These low molecular weight GTP-binding proteins play key roles in numerous signal transduction pathways stimulated upon activation of cell surface receptors by ligand binding. Thus, Ras/Rho proteins eventually regulate cell proliferation, tumor progression and cell death induced by anticancer therapeutics. Lipid modification of Ras/Rho proteins at their C-terminal CAAX-box is essential for their correct intracellular localization and function. Therefore, pharmacological inhibition of the isoprene metabolism is anticipated to impact the manifold biological functions attributed to Ras/Rho proteins. Here, the pros and cons of compounds that interfere with the mevalonate pathway for cancer treatment are summarized and discussed.

Keywords: Mevalonate pathway, protein prenylation, GTP-binding proteins, metastasis, anticancer drug resistance


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy